EyePoint Completes Enrollment of Pivotal Phase 3 Trials for Wet Age-Related Macular Degeneration Treatment

EyePoint Pharmaceuticals has completed enrollment of its Phase 3 pivotal program for DURAVYU in wet age-related macular degeneration (AMD). The LUCIA trial enrolled over 400 patients in seven months, making it one of the fastest enrolling Phase 3 programs for wet AMD. Interim analysis confirmed no changes to the protocol and recommended continuation of the trial. Topline 56-week data for LUGANO is expected in mid-2026, with LUCIA to follow closely. DURAVYU has demonstrated a favorable safety and tolerability profile in over 190 patients across four clinical trials.